Blastolysin - hepaton - promolan is a traditional remedy to treat and prevent chorioepithelioma especially in mild and moderate cases. This remedy has been proved to apply in benign prostatic hyperplasia. Evaluation after treatment by taking drug continuously in three months: Obstacle and irritable symptoms reduce in almost patients. Volume of prostate in echography image became significantly smaller. Initial results: very good 9 cases (19.1%), good 19 cases (40.4%), moderate is 16 cases (34.0%), poor 3 cases (6.3%). This remedy is not poisonous is widely indicated and suitable for many kind of patients such as elder patients, suffering from many diseases, no indication or unwillingness for operation... It costs less than ongoing therapy. As being hypertrophy prostate is current subject, many doctors and even patients concerned with, blastolysin therapy should be studied further.
Prostatic Hyperplasia ; therapy

From 6/1981 to 6/1996 a total of 978 consecutive patients (mean age: 69) presenting with bladder outlet obstructive were admitted to Viet Duc hospital for elective transurethral resection of prostate). The feagure of TURP were increasing from year to year and the TURP/ open surgery ratio was 80% in 1996. The procedures were performed with low mortality (0.3%) and low morbidity (bleeding 0.6%, capsular perforation (0.7%). TURP syndrome (0.3%), dysuria (1.8%) incontinence (1.1%), urethral stricture (1.5%) Hospital stay: 5(2 days. Overall outcome: good: 77%, moderate 19%; unsatis factory: 4%.
Prostatic Hyperplasia ; therapy ; surgery

Transurethral electrovaporisation of prostate (TVP or TUVP) is a new modification of transurethral resection of prostate (TURP). The goal of TVP in benign prostatic hyperplasia (BHP) is reduce the incidence of TURP complications. From 1996 to June 1997, the first time 12 patients have been indicated TVP for BHP in Cho Ray Hospital. The participants included those who have been not operated and those who have been operated using TURP previously. Several kinds of electrodes were used. The roller type was better but it makes the time of TVP longer. The sharp type is easier to cause complications. Perforation of capsule occurred in one patient.
Prostatic Hyperplasia ; therapy

Humans ; Laser Therapy ; Male ; Prostatic Hyperplasia ; surgery

PURPOSE: The aim of this study was to evaluate the efficacy of a combination drug therapy (tamsulosin plus finasteride) for benign prostatic hyperplasia, with a small prostate volume of less than 40 grams. MATERIALS AND METHODS: One hundred and twenty-three patients, with symptomatic benign prostatic hyperplasia of less than 40 grams, were analysed. Group 1 (n=67) had been treated with a combination of finasteride (5mg/day) and tamsulosin (0.2mg/ day), and Group 2 (n=56) with tamsulosin only (0.2mg/day) over a 12 month period. The patients were periodically assessed by IPSS (international prostate symptom score), uroflowmetry and residual urine, during the treatment period. RESULTS: The mean changes in the total symptom score, obstructive and irritative symptom score for group 1 and group 2 at 1 year were -7.21+/-7.44 (39.86%), -4.79+/-5.07 (45.02%) and -2.42+/-3.25 (48.11%), and -7.39+/-9.98 (43.06%), -4.82+/-6.91 (45.21%) and -2.39+/-4.00 (37.82%) points, respectively. The mean changes in the peak urinary-flow rates and postvoid residual urine for group 1 and group 2 at 1 year were 2.07+/-5.42 (16.65%)ml/s and -31.58+/-60.99 (56.47%)ml, and 2.38+/-6.57 (16.53%)ml/s and -34.78+/-86.77 (50.24%)ml, respectively. The effects of the combination of finasteride and tamsulosin were no greater than the tamsulosin monotherapy (p>0.01). CONCLUSIONS: A combination of finasteride and tamsulosin is no more effective than tamsulosin alone, in patients with benign prostatic hyperplasia, with a prostate volume of less than 40 grams.
Drug Therapy, Combination ; Finasteride* ; Humans ; Prostate* ; Prostatic Hyperplasia*

Disease Progression ; Humans ; Male ; Prostatic Hyperplasia ; therapy ; Transurethral Resection of Prostate

China ; Humans ; Laser Therapy ; Male ; Prostatic Hyperplasia ; surgery

Humans ; Male ; Practice Guidelines as Topic ; Prostatic Hyperplasia ; diagnosis ; therapy

Prostatic diseases and erectile dysfunction (ED) are common diseases in urology and andrology. Basic and clinical studies have proved that there is a close relationship between the two. This article reviews the mechanism, diagnosis and treatment of ED caused by several prostatic diseases, such as acute prostatitis, chronic prostatitis, benign prostate hyperplasia and prostate cancer.
Chronic Disease ; Erectile Dysfunction ; diagnosis ; etiology ; therapy ; Humans ; Male ; Prostatic Diseases ; complications ; Prostatic Hyperplasia ; complications ; Prostatic Neoplasms ; complications ; Prostatitis ; complications

The basic theory of high power green laser equipment for prostate hyperplasia therapy and the components of the system developed are introduced. Considering the requirements of the clinical therapy, the working process of the high power green laser apparatus are designed and the laser with stable output at 120 W is achieved. The controlling hardware and application software are developed, and the safety step is designed. The high power green laser apparatus manufactured with characteristics of stable output, multifunctional and friendly interface provides a choices of prostate hyperplasia therapy for using nationalization instrument.
Humans ; Laser Therapy ; Lasers ; Male ; Patient Safety ; Prostatic Hyperplasia ; therapy ; Software